<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707523</url>
  </required_header>
  <id_info>
    <org_study_id>FWA00005960</org_study_id>
    <nct_id>NCT02707523</nct_id>
  </id_info>
  <brief_title>Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-Induced (Respiratory Syncytial Virus - Induced) Respiratory Failure In Children</brief_title>
  <official_title>Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-Induced Respiratory Failure In Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will be a randomized, double masked, placebo-controlled pilot trial of
      azithromycin treatment in children with RSV-induced respiratory failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will be enrolled from the Pediatric Intensive Care Unit (PICU) at
      Children's of Alabama. Samples collected will be analyzed in the PI's lab at the University
      of Alabama at Birmingham. Drug pharmacokinetics will be performed at the Pharmaceutical
      Sciences Research Institute of Samford University, Birmingham, AL.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study at day 1</measure>
    <time_frame>baseline to day 1</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, serum AZM levels will be measured on day 1. The mean azithromycin (AZM) serum levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean oxygenation support between the three study arms</measure>
    <time_frame>baseline to last dose administered, an average of 3 weeks</time_frame>
    <description>Oxygenation saturation is measured daily while subject is being dosed. These will be measured in as fracture of inspired oxygen (Fi02). The normal FiO2 on room air is .209 (20.9% oxygen in the air)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean MOSF scores between the three study arms</measure>
    <time_frame>baseline to last dose administered, an average of 3 weeks</time_frame>
    <description>Multiple Organ System Failure (MOSF) scores is taken daily until discharge. The scores are as follows: 0 points: 0% mortality, 2 days ICU stay; 1 - 4 points: ICU mortality 1 -2 %, ICU stay 3 days; 5 - 8 points ICU mortality 3 - 5%, ICU stay 6 days; 9 - 12 points: ICU mortality 25%, ICU stay 10 days; 13 - 16 points: ICU mortality 50 %, ICU stay 17 days; 17 - 20 points: ICU mortality 75 %, ICU stay 21 days; 21 - 24 points: ICU mortality 100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 1</measure>
    <time_frame>baseline to day 1</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, aspirate AZM levels will be measured on days 1 until subject discharged. The mean AZM tracheal aspirate levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study</measure>
    <time_frame>baseline to day 1</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, nasal AZM levels will be measured on days 1 or until subject discharged. The mean AZM nasal levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 2, if still hospitalized</measure>
    <time_frame>2 days after starting therapy, if still hospitalized</time_frame>
    <description>To examine the delivery of the AZM to the lungs, serum AZM levels will be measured on day 2 if not discharged. The mean azithromycin (AZM) serum levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 3, if still hospitalized</measure>
    <time_frame>3 days after starting therapy, if still hospitalized</time_frame>
    <description>To examine the delivery of the AZM to the lungs, serum AZM levels will be measured on day 3 until discharged. The mean azithromycin (AZM) serum levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 5, if still hospitalized</measure>
    <time_frame>5 days after starting therapy, if still hospitalized</time_frame>
    <description>To examine the delivery of the AZM to the lungs, serum AZM levels will be measured on day 5 until subject discharged. The mean azithromycin (AZM) serum levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 7, if still hospitalized</measure>
    <time_frame>7 days after starting therapy, if still hospitalized</time_frame>
    <description>To examine the delivery of the AZM to the lungs, serum AZM levels will be measured on day 7 until subject discharged. The mean azithromycin (AZM) serum levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 14, if still hospitalized</measure>
    <time_frame>14 days after starting therapy, if still hospitalized</time_frame>
    <description>To examine the delivery of the AZM to the lungs, serum AZM levels will be measured on day 14 until subject discharged. The mean azithromycin (AZM) serum levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean serum AZM levels to the lungs while subjects hospitalized between the three arms of the study on day 21, if still hospitalized</measure>
    <time_frame>21 days after starting therapy, if still hospitalized</time_frame>
    <description>To examine the delivery of the AZM to the lungs, serum AZM levels will be measured on day 21 until subject discharged. The mean azithromycin (AZM) serum levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 2</measure>
    <time_frame>baseline to day 2</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, aspirate AZM levels will be measured on day 2 until subject discharged. The mean AZM tracheal aspirate levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 3 if still hospitalized</measure>
    <time_frame>baseline to day 3</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, aspirate AZM levels will be measured on day 3 until subject discharged. The mean AZM tracheal aspirate levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 5 if still hospitalized</measure>
    <time_frame>baseline to day 5</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, aspirate AZM levels will be measured on day 5 and weekly until subject discharged. The mean AZM tracheal aspirate levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 7 if still hospitalized</measure>
    <time_frame>baseline to day 7</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, aspirate AZM levels will be measured on day 7 until subject discharged. The mean AZM tracheal aspirate levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 14 if still hospitalized</measure>
    <time_frame>baseline to day 14</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, aspirate AZM levels will be measured on day 14 until subject discharged. The mean AZM tracheal aspirate levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean tracheal aspirate AZM levels while subjects hospitalized between the three arms of the study at day 21 if still hospitalized</measure>
    <time_frame>baseline to day 21</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, aspirate AZM levels will be measured on day 21 until subject discharged. The mean AZM tracheal aspirate levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study, at 3 days if not discharged</measure>
    <time_frame>baseline to day 3</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, nasal AZM levels will be measured on day 3 or until subject discharged. The mean nasal AZM nasal levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study, at 5 days if not discharged</measure>
    <time_frame>baseline to day 5</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, nasal AZM levels will be measured on days 1, 3, and 5 or until subject discharged. The mean nasal AZM nasal levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study, at 7 days if not discharged</measure>
    <time_frame>baseline to day 7</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, nasal AZM levels will be measured on day 7until subject discharged. The mean nasal AZM nasal levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study, at 14 days if not discharged</measure>
    <time_frame>baseline to day 14</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, nasal AZM levels will be measured on day 14 until subject discharged. The mean nasal AZM nasal levels will be compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the mean nasal AZM levels while subjects hospitalized between the three arms of the study, at 21 days if not discharged</measure>
    <time_frame>baseline to day 21</time_frame>
    <description>To examine the delivery of the Azithromycin to the lungs, nasal AZM levels will be measured on day 21 until subject discharged. The mean nasal AZM nasal levels will be compared between treatment groups</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Respiratory Syncytial Virus</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo controlled (normal saline) daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin (10 mg/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg/kg IV Azithromycin daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin (20 mg/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg/kg IV Azithromycin daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 10 mg</intervention_name>
    <arm_group_label>Azithromycin (10 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 20mg</intervention_name>
    <arm_group_label>Azithromycin (20 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to the PICU with RSV infection

          -  Randomization and drug/placebo initiation within 48 hours of admission to Pediatric
             Intensive Care Unit

        Exclusion Criteria:

          -  Azithromycin use within 7 days of PICU admission

          -  Contraindication to azithromycin use including:

               -  Patients with electrocardiogram QT interval corrected for heart rate (Qtc) â‰¥ 450
                  ms

               -  Patients with significant hepatic impairment (direct bilirubin &gt;1.5 mg/dL)

               -  Known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide
                  drug

               -  Cardiac arrhythmia

          -  History of pyloric stenosis

          -  Immunocompromised children (any cause)

          -  Current use of any medication known to cause QT prolongation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Kong, MD</last_name>
    <phone>(205) 638-9387</phone>
    <email>mkong@uab.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UAB</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Kong, MP</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Michele Kong</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>RSV</keyword>
  <keyword>respiratory support</keyword>
  <keyword>RSV induced respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

